[gpt3]Summarize this content to 100 words:
In an unexpected move, the U.S. Food and Drug Administration announced plans this week to reduce — and possibly replace — animal testing with other methods for developing certain medicines in a bid to lower R&D costs and, eventually, the prices for prescription drugs.
The agency will encourage researchers to use computer modeling and artificial intelligence to predict how a drug will perform, as well as organs-on-a-chip, which are miniaturized devices that mimic organs and tissues. And to determine effectiveness, the FDA will begin using existing, real-world safety data from other countries where a drug has already been studied in humans.
“For too long, drug manufacturers have performed additional animal testing of drugs that have data in broad human use internationally. This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use,” said FDA Commissioner Martin Makary in a statement.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
[/gpt
Source link